Literature DB >> 15893682

Multiple sclerosis and spasticity.

Jodie K Haselkorn1, Sharon Loomis.   

Abstract

Spasticity is a common impairment in MS. It can result in significant medical complications and is associated with increased disability. Treatment strategies include skilled rehabilitation strategies, neuromuscular blocks, oral agents, intrathecal management, and surgery. Rehabilitation strategies are central, whereas other strategies are added based on the level of impairment and functional loss. Treatment strategies for spasticity management are far from optimal and are complicated in MS as a result of lesions in the brain and the spinal cord. Pharmaceutical management in MS is complicated by the numerous secondary impairments in MS and its associated polypharmacy.Head-to-head studies of the various agents are rare. The studies that exist are small and do not point to any one strategy over another. Although management is difficult, it is essential for the health, functional status, and well-being of the individual who has MS. Providers must use well-developed clinical skills to arrive at optimal individualized treatment programs and monitor them frequently. For spasticity that is unresponsive, referral to a MS Center with a spasticity program is ideal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893682     DOI: 10.1016/j.pmr.2005.01.006

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  7 in total

1.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

Review 2.  Assessment and Measurement of Spasticity in MS: State of the Evidence.

Authors:  Cinda L Hugos; Michelle H Cameron
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-30       Impact factor: 5.081

3.  Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study.

Authors:  Antonio Carotenuto; Teresa Costabile; Mario De Lucia; Marcello Moccia; Fabrizia Falco; Martina Petruzzo; Marcello De Angelis; Cinzia Valeria Russo; Francesco Saccà; Roberta Lanzillo; Vincenzo Brescia Morra
Journal:  J Neurol       Date:  2020-03-02       Impact factor: 4.849

4.  The symptomatic management of multiple sclerosis.

Authors:  Randall T Schapiro
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

5.  A group-delivered self-management program reduces spasticity in people with multiple sclerosis: A randomized, controlled pilot trial.

Authors:  Cinda L Hugos; Dennis Bourdette; Yiyi Chen; Zunqiu Chen; Michelle Cameron
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-03-23

6.  Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany.

Authors:  Thomas Henze; Sylvia von Mackensen; Gerald Lehrieder; Uwe K Zettl; Carmen Pfiffner; Peter Flachenecker
Journal:  Health Qual Life Outcomes       Date:  2014-08-01       Impact factor: 3.186

7.  MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial.

Authors:  Cinda L Hugos; Michelle H Cameron
Journal:  BMC Neurol       Date:  2020-10-07       Impact factor: 2.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.